Published in Healthcare Finance, Tax and Law Weekly, September 17th, 2008
"We are pleased to advance our lead drug candidate into clinical trials," said Rachel King, Chief Executive Officer of GlycoMimetics. "GMI-1070 possesses excellent drug-like properties and has demonstrated potency in pre-clinical studies of vaso-occlusive crisis as well as in other disease indications."
The Phase 1 trial will evaluate the safety and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.